Devopharma ApS: Financial statements 2020
CVR: 38968254
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Devopharma ApS (CVR 38968254) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2020 report amounted to DKK 40,625. The solvency ratio was 40.6%.
- Gross Profit
- DKK -3,125
- Profit/Loss
- DKK -3,125
- Equity
- DKK 40,625
- Total Assets
- DKK 100,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -3 t. | -3 t. | 41 t. | 0 |
| 2019 | - | -3 t. | -3 t. | 44 t. | 0 |
How creditworthy is Devopharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Devopharma ApS has published its annual report for 2019. Gross profit came to DKK -3,125, and the net result was DKK -3,125.
About Devopharma ApS
Devopharma ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company's owners include JARCO HOLDING ApS, HN HOLDING 2010 ApS and Friendly Holding ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2025 report amounted to DKK 25,000.